President Trump says all 50 states are joining his Medicaid drug-pricing model, putting nationwide weight behind lower costs while undisclosed deal terms leave savings questions open.
President Donald Trump announced Friday that every state will take part in the Medicaid “GENEROUS” model, PBS NewsHour reported. The program targets selected prescription drugs through prices tied to those paid in other countries.
The nationwide participation gives the administration a broad platform for its most-favored-nation policy. But the savings remain difficult to judge because the drug companies, covered medications, comparison countries and contract terms have not been fully disclosed.
Trump made the announcement in the Oval Office with Health and Human Services Secretary Robert F. Kennedy Jr. and Medicare and Medicaid chief Mehmet Oz. Trump said the policy could free state money for other needs.
Medicaid is jointly funded by state and federal taxpayers and serves people with low incomes. Patients usually pay only a few dollars for prescriptions, so much of the direct financial benefit would flow to government budgets.
The GENEROUS model seeks to lower the net price of selected drugs to levels available in certain foreign markets. All 50 states have agreed to participate, giving the plan reach across Republican-led and Democratic-led states alike.
Breitbart reported that Washington, D.C., and Puerto Rico are also included. Oz said every state had joined, while the program will use drug-company rebates to bring Medicaid’s final cost down.
Those rebates are aimed at expensive brand-name medications. Under the model, a participating company would return money if Medicaid’s final price exceeded the applicable most-favored-nation level.
That approach matters because it focuses on what taxpayers ultimately pay, not merely a drug’s listed price. If the rebates work as described, state Medicaid programs could keep more money for other medical services.
Trump put that argument plainly during the announcement. As AP reported, he said:
“Every state will have the ability to use those extra billions of dollars to invest in other healthcare improvements or something else.”
The administration also sees a clear political benefit. Trump said, “This one thing alone should win us the midterms,” linking the policy to voters’ concerns about household costs.
Trump has reached pricing agreements with 26 pharmaceutical companies since late September 2025, Breitbart and the New York Post reported. Some companies also agreed to provide discounts for uninsured Americans through TrumpRx.
The New York Post reported that the Medicaid programs involved serve roughly 70 million Americans. It placed projected Medicaid savings at $64 billion over a decade.
A broader White House estimate put possible federal savings from pharmaceutical pricing agreements at $529 billion over 10 years. The administration’s figures have not been independently verified, and the underlying deal terms remain private.
The difference between the estimates needs a plain explanation. One figure concerns Medicaid, while the larger projection covers broader federal savings, but the public still lacks enough detail to test either calculation.
Commercial contracts often contain private pricing terms. That does not erase the government’s duty to show taxpayers how it produced a claim worth hundreds of billions of dollars.
Kathy Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, said pressure is growing for more data. She also questioned how Congress could make the pricing arrangements permanent without seeing their contents.
“He is saying Congress should codify all of his MFN arrangements,” Hempstead said. “But it's kind of unreasonable because it's not clear what Congress would actually do. No one knows what is in these deals.”
Her concern goes beyond the headline savings. The available terms do not show how long the lower prices will last or how much each state would keep.
The public also does not know which selected medications qualify, which foreign prices set the benchmark or which provisions govern the company rebates. Those details will decide whether the model produces lasting savings or a shorter-lived discount.
The administration has defended the lack of disclosure by pointing to commercially sensitive information. White House spokesman Kush Desai also noted that drug agreements negotiated during former President Joe Biden’s term withheld such material.
That comparison answers part of the political criticism. It does not settle the budget question. Congress and state governments still need enough information to judge the savings without forcing companies to publish every confidential contract term.
JD Hayworth, a former Republican congressman and spokesman for the Pharmaceutical Reform Alliance, called the announcement “meaningful progress, but that progress remains incomplete.”
His group pointed to millions of Americans outside government health programs who also want relief from high prescription costs. Medicaid savings can protect taxpayers and state budgets, but they do not automatically lower every family’s pharmacy bill.
That limitation does not diminish the scale of nationwide state participation. It does define the next test: whether the administration can turn its drug-company agreements into broader and durable savings.
Trump has secured nationwide cooperation for a serious cost-cutting effort. Now taxpayers deserve clear numbers showing that the promised savings reach the public purse.
